Rapport Therapeutics (RAPP) Cash from Operations (2023 - 2026)
Rapport Therapeutics (RAPP) reported Cash from Operations of 13061000.0 for Q1 2026, up 35.46% year-over-year from 9641974.87 in Q1 2025, and up 47.12% quarter-over-quarter from 24701000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Cash from Operations (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Cash from Operations data on file, last reported at 13061000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 13061000.0, up 35.46% year-over-year; the trailing twelve-month figure through Mar 2026 was 80297000.0 (down 19.05% YoY), and the FY2025 annual result was 87473000.0, down 34.93% from the prior year.
- Cash from Operations improved to 13061000.0 in Q1 2026 per RAPP's latest filing, from 24701000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 5424000.0 in Q3 2023 and troughed at 25070000.0 in Q2 2025.
- A 4-year average of 16467545.45 and a median of 16415000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2026: Cash from Operations sank 202.64% in 2024, then jumped 35.46% in 2026.
- A 4-year view of Cash from Operations shows it stood at 10357000.0 in 2023, then slumped by 39.48% to 14446000.0 in 2024, then plunged by 70.99% to 24701000.0 in 2025, then jumped by 47.12% to 13061000.0 in 2026.
- Business Quant data shows RAPP's Cash from Operations at 13061000.0 in Q1 2026, 24701000.0 in Q4 2025, and 17465000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | -13.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.06 Mn |
| Mar 31, 2026 | -13.06 Mn |
| Dec 31, 2025 | -24.70 Mn |
| Dec 31, 2025 | -24.70 Mn |
| Sep 30, 2025 | -17.47 Mn |
| Sep 30, 2025 | -17.47 Mn |
| Jun 30, 2025 | -25.07 Mn |
| Jun 30, 2025 | -25.07 Mn |
| Mar 31, 2025 | -20.24 Mn |
| Mar 31, 2025 | -20.24 Mn |
| Dec 31, 2024 | -14.45 Mn |
| Dec 31, 2024 | -14.45 Mn |
| Sep 30, 2024 | -16.42 Mn |
| Sep 30, 2024 | -16.42 Mn |
| Jun 30, 2024 | -16.35 Mn |
| Jun 30, 2024 | -16.35 Mn |
| Mar 31, 2024 | -17.62 Mn |
| Mar 31, 2024 | -17.62 Mn |
| Dec 31, 2023 | -10.36 Mn |
| Dec 31, 2023 | -10.36 Mn |